A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1–7 (TXA-127) for the treatment of severe COVID-19

An investigator-initiated new drug application (IND) was approved by the Food and Drug Administration (FDA), and the study was approved by the Columbia University Irving Medical Center (CUIMC) Institutional Review Board (IRB #AAAT0535). [...]morbidity and mortality improved by the time patients were...

Full description

Saved in:
Bibliographic Details
Published inCritical care (London, England) Vol. 26; no. 1; pp. 1 - 229
Main Authors Wagener, Gebhard, Goldklang, Monica P, Gerber, Adam, Elisman, Katerina, Eiseman, Katherine A, Fonseca, Laura D, D'Armiento, Jeanine M
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 28.07.2022
BioMed Central
BMC
Subjects
Angiotensin
Coronaviruses
Correspondence
COVID-19
Critical care
Drug therapy
Enzymes
FDA approval
Health aspects
Kidney diseases
Length of stay
Mortality
Pathophysiology
Polymerase chain reaction
Severe acute respiratory syndrome coronavirus 2
United States
Online AccessGet full text

Cover

More Information
Summary:An investigator-initiated new drug application (IND) was approved by the Food and Drug Administration (FDA), and the study was approved by the Columbia University Irving Medical Center (CUIMC) Institutional Review Board (IRB #AAAT0535). [...]morbidity and mortality improved by the time patients were recruited into this study. [...]in this proof-of-concept study, TXA-127 was safe to administer in patients with severe COVID-19 infection.
Bibliography:SourceType-Other Sources-1
ObjectType-Correspondence-1
ObjectType-News-2
content type line 66
ObjectType-Article-3
ISSN:1364-8535
1364-8535
1466-609X
1366-609X
DOI:10.1186/s13054-022-04096-9